Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National University Hospital, Singapore National Healthcare Group, Singapore |
---|---|
Information provided by: | National University Hospital, Singapore |
ClinicalTrials.gov Identifier: | NCT00212108 |
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors.
Study hypothesis: Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer.
Condition | Intervention | Phase |
---|---|---|
Nasopharyngeal Carcinoma |
Drug: celecoxib, gefitinib |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 |
Estimated Enrollment: | 20 |
Study Start Date: | November 2003 |
Estimated Study Completion Date: | August 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ross Soo, MD | 65 67795555 | soolk@nuh.com.sg |
Singapore | |
National University Hospital | Recruiting |
Singapore, Singapore, 119074 | |
Contact: Ross Soo, MD 65 67795555 soolk@nuh.com.sg | |
Principal Investigator: Ross Soo, MD | |
Sub-Investigator: Goh Boon Cher, MD | |
Sub-Investigator: Thomas Loh, MD |
Principal Investigator: | Ross Soo, MD | National University Hospital, Singapore |
Responsible Party: | National University Hospital, Singapore ( Ross Soo, MD ) |
Study ID Numbers: | NP01/07/03 |
Study First Received: | September 13, 2005 |
Last Updated: | July 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00212108 |
Health Authority: | Singapore: Health Sciences Authority; Singapore: Domain Specific Review Boards |
celecoxib, NPC, gefitinib |
Celecoxib Nasopharyngeal carcinoma Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Pharyngeal Neoplasms |
Stomatognathic Diseases Gefitinib Pharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms, Glandular and Epithelial Carcinoma |
Anti-Inflammatory Agents Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Cyclooxygenase Inhibitors Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Neoplasms |
Neoplasms by Site Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Nasopharyngeal Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |